[go: up one dir, main page]

SE0300213D0 - Use of avian antibodies - Google Patents

Use of avian antibodies

Info

Publication number
SE0300213D0
SE0300213D0 SE0300213A SE0300213A SE0300213D0 SE 0300213 D0 SE0300213 D0 SE 0300213D0 SE 0300213 A SE0300213 A SE 0300213A SE 0300213 A SE0300213 A SE 0300213A SE 0300213 D0 SE0300213 D0 SE 0300213D0
Authority
SE
Sweden
Prior art keywords
infections
microbe
prophylaxis
igy
birds
Prior art date
Application number
SE0300213A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Larsson
Hans Kollberg
Original Assignee
Immun System Uppsala I M S Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immun System Uppsala I M S Ab filed Critical Immun System Uppsala I M S Ab
Priority to SE0300213A priority Critical patent/SE0300213D0/xx
Publication of SE0300213D0 publication Critical patent/SE0300213D0/xx
Priority to DE602004005963T priority patent/DE602004005963T2/de
Priority to US10/542,784 priority patent/US20060134101A1/en
Priority to PCT/SE2004/000133 priority patent/WO2004067035A1/fr
Priority to ES04706915T priority patent/ES2285419T3/es
Priority to EP04706915A priority patent/EP1589995B1/fr
Priority to AT04706915T priority patent/ATE359820T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23Immunoglobulins specific features characterized by taxonomic origin from birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0300213A 2003-01-30 2003-01-30 Use of avian antibodies SE0300213D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0300213A SE0300213D0 (sv) 2003-01-30 2003-01-30 Use of avian antibodies
DE602004005963T DE602004005963T2 (de) 2003-01-30 2004-01-30 Verwendung von vogelantikörpern
US10/542,784 US20060134101A1 (en) 2003-01-30 2004-01-30 Use of avian antibodies
PCT/SE2004/000133 WO2004067035A1 (fr) 2003-01-30 2004-01-30 Utilisation d'anticorps aviaires
ES04706915T ES2285419T3 (es) 2003-01-30 2004-01-30 Uso de anticuerpos aviares.
EP04706915A EP1589995B1 (fr) 2003-01-30 2004-01-30 Utilisation d'anticorps aviaires
AT04706915T ATE359820T1 (de) 2003-01-30 2004-01-30 Verwendung von vogelantikörpern

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300213A SE0300213D0 (sv) 2003-01-30 2003-01-30 Use of avian antibodies

Publications (1)

Publication Number Publication Date
SE0300213D0 true SE0300213D0 (sv) 2003-01-30

Family

ID=20290238

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300213A SE0300213D0 (sv) 2003-01-30 2003-01-30 Use of avian antibodies

Country Status (7)

Country Link
US (1) US20060134101A1 (fr)
EP (1) EP1589995B1 (fr)
AT (1) ATE359820T1 (fr)
DE (1) DE602004005963T2 (fr)
ES (1) ES2285419T3 (fr)
SE (1) SE0300213D0 (fr)
WO (1) WO2004067035A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008835A2 (fr) * 2005-07-10 2007-01-18 Adaptive Spectrum And Signal Alignment, Inc. Estimation de systeme dsl
US20070065452A1 (en) 2005-07-25 2007-03-22 Avianax Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
US8877187B2 (en) 2005-07-25 2014-11-04 Avianax, Llc Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
GB2482535A (en) * 2010-08-05 2012-02-08 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
GB2482536B (en) 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
PH12013501040A1 (en) 2010-11-23 2022-10-24 Pantheryx Inc Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
EP2968543B1 (fr) * 2013-03-15 2024-08-07 Camas Incorporated Procédés et compositions pour réduire des micro-organismes dans l'oropharynx, le nasopharynx et les cavités buccales
US12263192B2 (en) 2019-02-26 2025-04-01 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
WO2021112174A1 (fr) * 2019-12-03 2021-06-10 国立大学法人東海国立大学機構 Procédé thérapeutique antimicrobien optique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599539A (en) * 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
ZA929143B (en) * 1992-11-25 1993-08-16 Michael Anthony Folan Agents for use in the prophylaxis and therapy of fungal infections.
SE9701026D0 (sv) * 1997-03-20 1997-03-20 Immun System Ims Ab use of avian antibodies

Also Published As

Publication number Publication date
US20060134101A1 (en) 2006-06-22
WO2004067035A1 (fr) 2004-08-12
ES2285419T3 (es) 2007-11-16
ATE359820T1 (de) 2007-05-15
EP1589995B1 (fr) 2007-04-18
DE602004005963T2 (de) 2008-01-17
EP1589995A1 (fr) 2005-11-02
DE602004005963D1 (de) 2007-05-31

Similar Documents

Publication Publication Date Title
Abbas et al. IgY antibodies for the immunoprophylaxis and therapy of respiratory infections
Nguyen et al. Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
Linderman et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season
Friesen et al. A common solution to group 2 influenza virus neutralization
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
CA3081125C (fr) Fragment variable a chaine unique anti-antigene de maturation des lymphocytes b (bcma) entierement humain, et application associee
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
Nagarajan et al. Monoclonal antibodies for the prevention of rabies: theory and clinical practice
EA201000424A1 (ru) Антитела к il-23
Polanowski et al. Immunomodulatory activity accompanying chicken egg yolk immunoglobulin Y
MX2009006066A (es) Tratamiento de cerdos con el antigeno pcv.
NO20084539L (no) Humaniserte monoklonale antistoffer til hepatocyttvekstfaktor
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
Sudjarwo et al. The potency of chicken egg yolk immunoglobulin (IgY) specific as immunotherapy to Mycobacterium tuberculosis infection
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
SE0300213D0 (sv) Use of avian antibodies
Lachmann The use of antibodies in the prophylaxis and treatment of infections
da Rocha et al. Development of IgY antibodies against anti-snake toxins endowed with highly lethal neutralizing activity
Redwan et al. Ovine anti-rabies antibody production and evaluation
BRPI0516677A (pt) nonadepsipeptìdeos acilados como derivados de lysobactin
WO2023280297A9 (fr) Anticorps cd19 et son application